Importantly, studies have shown that EGFR TKIs extend both progression-free survival (PFS) and overall survival (OAS) compared to comparator arms in trials involving EGFR-mutant advanced NSCLC patients [5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.